Occupational health nurses have undoubtedly grown accustomed to a daily barrage of questions about cholesterol now that cholesterol is so much a part of our everyday vocabulary. This high level of cholesterol awareness and the new treatment guidelines from the National Cholesterol Education Program (NCEP) (Schucker, 1987) afford occupational health nurses increasing opportunities for teaching cardiovascular risk reduction in the workplace. Such teaching opportunities require knowledge of the basic tenets of diet and drug therapy for hypercholesterolemia in a perspective which is sensitive to the complex dynamics of behavior change and client compliance.
DIET: THE FIRST STEP
The NCEP guidelines set forth clear and logical steps for client screening and identification of individuals with at-risk cholesterol levels (see LaRosa, J.H., et aI, "Elevated Blood Cholesterol: A Risk Factor for Coronary Heart Disease," pages 211-
The majority of persons with moderate elevations of cholesterol will be able to decrease their blood cholesterol to a desirable level with a combination of diet, weight loss, and exercise.
215, in this issue). These screening procedures are designed to identify those individuals who should initiate dietary therapy for their cholesterol elevation and who ultimately can benefit from such dietary changes.
It is important for nurses to know three key principles about dietary treatment for high blood cholesterol levels. Diet is always the first step in the treatment of hypercholesterolemia. Discussions and decisions about drug therapy should be deferred until an adequate trial on the low cholesterol, low fat diet has been completed.
The majority of persons with moderate elevations of cholesterol will be able to decrease their blood cholesterol to a desirable level with a combination of diet, weight loss, and exer-cise. This is usually very welcome news to the individuals identified as having at-risk cholesterol levels.
The diet should be continued in most cases for 6 months before medication is considered. This recommended period of time allows individuals to adapt gradually to new eating patterns and also discourages the use of cholesterol lowering medication for those who can lower their cholesterol with diet alone. In the occupational health setting, nurses can be very instrumental in instituting procedures which assure that the person's progress is reviewed systematically after 6 months on the diet and then referring them to qualified health care providers for consideration of drug therapy.
DIET PRINCIPLES
Occupational health nurses who will be providing dietary counseling for employees need to understand the rationale for dietary intervention, the characteristics of the low cholesterol, low fat diet, and some specific facts about fats.
In most people, high blood cholesterol levels are caused by dietary excesses of foods high in saturated fatty acids, cholesterol, and calories. High levels of saturated fatty acids and cholesterol raise blood cholesterol levels by reducing low density lipoprotein (LDL) re-The development of heart disease is shown by three cross sections of coronary arteries. Left: a normal coronary artery; center: cholesterol laden plaque occludes more than half of the artery's lumen; right: complete occlusion of a coronary artery. ceptor activity and clearance of LDL from the blood stream. Excessive intake of calories and obesity raise blood cholesterol levels by stimulating an overproduction of LDL, which in turn raises LDL levels (\an Italie, 1987) . In general, cholesterol lowering diets focus on decreasing total fat in the diet, changing the balance of the types of foods in the diet, and keeping body weight at a desirable level (Table 1) . Unsaturated fats, which lower blood cholesterol, are substituted for saturated fats which raise blood cholesterol levels more than any other component of the diet. Foods high in dietary cholesterol are decreased as the intake of complex carbohydrates, such as fruits and whole grains, are increased. Calories also are controlled so that ideal body weight can be achieved and maintained. And, moderate exercise is encouraged.
Excellent teaching materials are available from the American Heart Association (1988) which offers two level s of the low fat, low cholesterol diet. These diets allow for a progressive reduction of saturated fats and cholesterol. The Step One diet restricts total fat intake to less than 30%, saturated fats to less than 10% of calories, and cholesterol to less than 300 g per day. The Step Two diet further reduces saturated fat to less than 7% of calories and cholesterol to less than 200 g per day.
BASIC FACTS ABOUT FATS
Three major food categories comprise the diet : fat, carbohydrate, and protein . Fat is the most concentrated source of calories with nine calories per gram, compared to four calories per gram for protein foods such as meat and four calories per gram for carbohydrates. Substituting carbohydrates for fats in the diet helps to maintain energy and proper nutrition, and reduces the total daily calories.
People need to understand that although the three different types of fat in the diet-saturated, monounsaturated, and polyunsaturated-all have nine calories per gram, they have different metabolic effects on the blood cholesterol. Saturated fats, which are actually triglycerides in the diet, are found in animal products and some plant oils. They raise blood cholesterol more than any component in the diet. In the Step One diet, saturated fats are decreased to less than 10% of the total daily calories.
Polyunsaturated fats, like saturated fats, are actually in the form of triglycerides in the diet. They are good substitutes for saturated fats because they lower total and LDL cholesterol. In the Step One and Two diets they may, however , lower high density lipoprotein (HDL) cholesterol as well . Polyunsaturated fats can be increased in the diet up to 10% of total daily calories.
Monounsaturated fats can provide nutritional variety and additional cholesterol lowering benefits. Some studies have shown that the oleic acid in monounsaturated fats can decrease LDL levels as much as polyunsaturated fats. In addition , monounsaturated fats may help to maintain, and in some cases, actually raise HDL levels .
Dietary cholesterol has been shown to raise LDL cholesterol levels, although this response varies from person to person. Some studies have shown that dietary cholesterol also increases postprandial lipoproteins , such as ch ylomicron remnants , which may increase cardiovascular risk. Dietary cholesterol is restricted to 300 mg per day in the Step One diet, and in the more restricted Step Two diet, to 200 mg per day.
The important points for nurses to stress during initial diet counseling are the different metabolic effects of the types of fat, the difference between saturated fat and dietary cholesterol, and the overall reduction of total fat in the diet.
MAKING HEALTHY FOOD CHOICES
What types of foods are allowed on the low cholesterol, low fat diet? To answer that question, review all of the following food categories with the client and provide reference materials on food choices.
Saturated Fats
Saturated fats are found primarily in foods of animal origin including dairy products that contain butter fat such as butter, whole milk, cream, and cheese; and protein foods such as beef, pork, fish, and poultry. The saturated fat content of these protein foods can be decreased by removing the skin from poultry and by choosing leaner cuts of meat.
Saturated fats are found also in three plant oils (coconut oil, palm oil, and palm kernel oil) which are frequently used in food products, as well as in hydrogenated vegetable oils. Cocoa butter, the main ingredient in chocolate, is also a saturated fat which raises blood cholesterol.
Polyunsaturated Fats
The two types of polyunsaturated fats are Omega 3 and Omega 6 fatty acids. These fats are soft or liquid at room temperature. The Omega 6 vegetable oils, which are rich in linoleic acid, help to lower blood cholesterol and can be added to the diet as a substitute for saturated fats. These include corn oil, safflower oil, sunflower seed oil, soybean oil, and sesame oil. The Omega 3 fatty acids are found primarily in fish oils as eicosapentanoic acid (EPA) and docosahaenoic acid (DHA).
Individuals may be encouraged to eat two to three fish meals a week, including fish such as tuna, salmon, or mackerel. Fish oil supplements, however, should be discouraged because they may have negative effects on lipid levels, blood clotting, infection rates, tumors, and cardiovascular risk. Until more research has been done, fish oil supplements should not be recommended.
Monounsaturated Fats
Monounsaturated fats, which contain primarily oleic acid, should comprise from 10% to 15% of the total calories in a cholesterol lowering diet. Oleic acid is the major fatty acid in olive oil, rapeseed or canola oil, and peanut oil.
Dietary Cholesterol
Cholesterol in the diet is found in animal products, including egg yolks; milk; cheese; butter; ice cream; organ meats such as liver, kidney, sweet breads, and brains; meat; poultry; fish; and shellfish. Egg yolks and organ meats are the Total cholesterol levels may be used to monitor the response to diet, but LDL levels should be used in making decisions about diet and drug therapy.
richest sources of dietary cholesterol. Shrimp and lobster are high in cholesterol, although they are low in total fat content. Since all meats, poultry, and fish contain dietary cholesterol and other types of fat, the
Step One Diet restricts the total daily intake of protein from these sources to 6 ounces of lean protein per day.
During diet instruction, nurses should emphasize the difference between dietary cholesterol and saturated fat. In addition, clients should be taught how to read ingredient labels. Remember to point out that food products marked "no cholesterol" may contain saturated fat.
Fiber
Fiber is the indigestible part of plants comprised of indigestible carbohydrates and lignin-the woody, noncarbohydrate part of plant walls. Insoluble fibers do not dissolve in water and cannot be broken down for digestion in the intestinal tract. A high intake of insoluble fiber results in an increase both in the bulk of stools and in the motility of food through the intestine.
Studies have shown that a high fiber intake is associated with less constipation and, possibly, less colon cancer. Insoluble fiber includes cellulose and lignin. Rich sources of these fibers are found in wheat bran, cereal grains, whole meal bread and flour, beans, nuts, beets, brussels sprouts, and fruits with seeds such as raspberries and strawberries.
Soluble fibers do not maintain their structure in the intestine, and become gel-like or gummy. Studies have shown that soluble fiber delays the passage of food through the intestine, thus slowing the digestion of carbohydrates into sugar. Since this process helps to keep blood sugar from rising rapidly after a meal, persons with diabetes mellitus are encouraged to increase their intake of insoluble fiber.
Other studies have shown that soluble fibers can lower blood cholesterol and triglyceride levels modestly through increased fecal excretion of bile acids, cholesterol containing substances that are required for fat digestion. Soluble fibers include hemicellulose, found in whole grain cereals, oat bran, cabbage, celery, leafy vegetables, melons, peaches, and pears; pectin found in apples, citrus fruits, grapes, and berries; mucilages found in bulking agents; and gums found in beans.
Although soluble fiber should be included in the diet in moderate amounts, persons should be discouraged from viewing fiber as a quick "cure all" for their elevated cholesterol. They should be encouraged to choose high fiber food carefully, since some oat bran products labeled as "healthy choices" actually contain high levels of saturated fat and calories.
Alcohol
The effect of alcohol on blood lipids is a subject of continuing debate. Studies have shown that alcohol does not affect LDL levels, but raises triglyceride and HDL levels. The mechanism for the rise in HDL and the possible protection it affords is unknown. Therefore, it is best to recommend that alcohol be consumed only in moderation, since a high consumption has many adverse consequences on health.
DIET THERAPY: WHAT TO EXPECT
Nurses can reinforce new eating habits by emphasizing that many persons with high blood cholesterol can achieve an average 10% to 15% reduction in LDL cholesterol on the
Step One diet. A modest amount of additional lowering may be achieved by adding soluble fiber such as oat bran cereal to the diet. With strict · adherence and weight loss, some persons can achieve more than a 30% reduction.
Lowering cholesterol through the diet can be achieved in some persons in as little as 2 weeks, while others may take longer to achieve the maxi-· mum effect on blood cholesterol levels. According to the NCEP guidelines, the cholesterol level should be measured after 3 to 4 weeks and again at 3 months after starting the diet. (Table 2) . This includes providing up to date information about the diet principles and food choices; monitoring their progress according to the guidelines established by NCEP; encouraging and supporting clients as they gradually adjust to new eating patterns; and referring clients to a healthcare provider for evaluation of their cholesterol if their level remains elevated after 6 months on the heart healthy diet.
DRUG THERAPY: WHEN DIET
IS NOT ENOUGH Many questions naturally arise after a person with elevated cholesterol has been following a low fat, low cholesterol diet for 6 months. How well have they followed the diet? Is the LDL level within the acceptable range? Is the person a candidate for drug therapy?
The new NCEP treatment guidelines provide answers to these questions with a standard treatment algorithm for drug therapy for hypercholesterolemia. These guidelines provide a framework which, in conjunction with clinical judgment, will assure clients of appropriate, state of the art care for their hypercholesterolemia.
According to the NCEP guidelines, a client should be considered a candidate for drug therapy if, after an adequate trial on diet therapy, LDL levels remain above the following: Decisions about initiating drug therapy are based on the level of LDL cholesterol. Clinical judgment is essential, however. HDL levels are taken into consideration in treating borderline cases in which the LDL remains close to the designated cut-off.
For example, a person with an LDL of 165 mg/dl, an HDL of 30 mg/dl, and a family history of premature coronary disease may be an appropriate candidate for drug therapy. And, another person with an LDL of 165 mg/dl, an HDL of 80, and no family history of heart disease may be more appropriately treated with a continuing program of diet modification and exercise.
When counseling clients, it is important for nurses to emphasize that the decision to begin any type of drug therapy should always be made carefuIly and cautiously with their Stoy healthcare provider. Since drug therapy for hypercholesterolemia is a life long therapy, every effort must be made to reduce the cholesterol level with diet, exercise, and weight reduction if needed.
GOALS OF THERAPY
The goals of drug therapy are similar to those of diet therapy and are also based on the level of LDL cholesterol as foIlows:
• LDL cholesterol < 160 mg/dl: in persons without CHD or two risk factors, one of which is the male sex. • LDL cholesterol <130 mg/dl: in persons with definite CHD or two other risk factors.
The guidelines also suggest that it may be desirable to lower LDL levels below these target values. Recent studies about the regression of heart disease have shown that lowering LDL levels to 100 mg/dl may reverse atherosclerosis in some persons with documented heart disease. However, no evidence suggests that lowering LDL below 100 mg/dl is beneficial or safe. Although a national consensus is lacking on lowering LDL to 100 mg/dl in persons with heart disease, many lipid specialists are lowering LDL to that level in high risk clients.
CHOLESTEROL LOWERING DRUGS
When developing its recommendations, the NCEP's Adult Treatment Panel considered not only the availability of drugs, but also their established efficacy, safety records, and proven effect on lowering CHD risk. Five major cholesterol lowering drugs were considered: bile acid sequestrants, nicotinic acid, HMG CoA reductase inhibitors (Iovastatin), gemfibrozil, and probucol (NCEP, 1987) .
Preferred Drugs
The drugs of first choice, as defined by NCEP, are drugs that have proven records for reducing CHD risk and for long term safety. For clients with high LDL levels and normal triglycerides «250 mg/dl), these drugs include the bile acid sequestrants, cholestyramine and colestipol, and nicotinic acid.
Originally used to treat biliary diseases in children, these drugs have been approved by the FDA for cholesterol lowering in adults for more than 20 years. In long term clinical trials they have been shown to be safe and effective in lowering both LDL cholesterol and CHD risk.
The primary action of the sequestrants is to bind bile acids in the small intestine. This binding interrupts the enterohepatic circulation of bile acids, leading to an increased production of bile acid from cholesterol in the liver. The decreased hepatic pool of cholesterol stimulates an increase in LDL receptor activity in the liver, which in turn increases the clearance of LDL from the plasma. Bile acid sequestrants can lower LDL by 15% to 30%.
Both bile acid sequestrants are supplied in powder form, which must be mixed with a cool liquid and consumed as a drink. The drugs are supplied in individual dose packets or bulk form with one packet or one scoop containing either 4 g of cholestyramine or 5 g of colestipol. A new 4 g candy bar Since drug therapy for hypercholesterolemia is a life long therapy, every effort must be made to reduce the cholesterol level with diet, exercise, and weight reduction if needed.
form of cholestyramine has become available recently.
The major advantages of the bile acid sequestrants are their safety and efficacy. They achieve their lipid lowering effects in the intestine, are not systemically absorbed, and cause no systemic toxicities. The major disadvantages of the sequestrants are cost, inconvenience, and possible gastrointestinal side effects.
Generally, the bulk form of the sequestrants is the least expensive, although a full 24 g per day dosage of cholestyramine (Questran) or colestipol (Coles tid) can cost over $1,000 per year. The new candy bar form of cholestyramine (Cholybar), a more expensive form of the drug which can cost more than $1 per bar, can be helpful as an adjunct to standard resin therapy for children, or for those who travel or eat out often.
Convenience is a factor in client adherence to bile acid sequestrant therapy. Since the drugs must be mixed with a liquid and consumed as a drink, some preparation time and effort is required. Nurses can teach clients about cues or reminders so they can remember to take their sequestrants within 30 minutes of a meal.
The most common side effects associated with bile acid sequestrants are related to the gastrointestinal system: constipation, bloating, nausea, and flatulence. Side effects can be mini-mized by starting with small doses of the drug (i.e., one packet with the morning and evening meal), and then increasing slowly over a period of several weeks. In addition, taking the drug with adequate fluid and fiber in the diet is helpful in reducing constipation, the most common side effect.
Several other factors must be considered with the bile acid sequestrants. They are contraindicated in individuals with marked hypertriglyceridemia (triglycerides over 500 mg/dl) or with severe constipation. The binding capacity of the sequestrants can affect the absorption of other drugs taken concurrently with the sequestrant. This includes digitoxin, warfarin, thyroxine, thiazide diuretics, beta blockers, dilantin, penicillin G, tetracycline, fat soluble vitamins A, D, K, and E, as well as other drugs. Although decreased absorption of fat soluble vitamins and folic acid has been reported in persons with liver or small bowel disease, routine vitamin supplementation is not required in healthy individuals during therapy with sequestrants.
The general rule is to instruct clients to take all other medications either 1 hour before or 2 to 4 hours after their bile acid sequestrants. This rule includes routine vitanuns.
Nicotinic acid, the water soluble B vitamin also known as niacin, has been used for many years as a lipid lowering agent. It is a drug of first choice because it is extremely effective and safe, and has been shown to reduce the risk of CHD.
Nicotinic acid has many benefits. Available without a prescription at an average cost of $400 per year for a therapeutic dose of up to 3 g, it is the least costly of all the lipid-lowering drugs. By decreasing the hepatic production of very low density lipoprotein (VLDL), nicotinic acid not only lowers total and LDL cholesterol, but it also lowers triglycerides and raises HDL cholesterol levels as well. Nicotinic acid can lower LDL levels as much as 30%.
To produce effective cholesterol lowering, the therapeutic dose of nicotinic acid is 1.5 g (1,500 mg) or more. Since nicotinic acid can cause severe flushing and itching, therapy with nicotinic acid should be initiated with a single dose of 100 to 250 mg per day. Since the flushing is prostaglandin mediated, it is helpful to instruct the client to take an aspirin or a nonsteroidal antiinflammatory preparation (unless contraindicated for other health reasons) 30 minutes before the nicotinic acid.
In addition, clients can be instructed to take their nicotinic acid on a full stomach and to begin therapy on a nonworking day to avoid any potential embarrassment that arises from the flushing. Flushing appears to be less with the timed-release preparations of nicotinic acid, although these preparations are more expensive.
The dose of nicotinic acid can be increased every 4 to 7 days until the therapeutic dose of 1.5 g to 2 g is reached. The dose can be increased to 3 g per day if sufficient LDL lowering has not been attained. Therapeutic doses of up to 6 g of nicotinic acid have been used in clinical studies and can be used cautiously in clients with severe cholesterol elevations. Nurses should emphasize that self care with therapeutic doses of niacin is dangerous.
Careful monitoring and follow up with a qualified health care provider is required with nicotinic acid therapy, because large doses can cause toxicities such as elevated liver function, hyperuricemia, hyperglycemia, flu syndrome, blurred vision, skin changes, and a number of gastrointestinal complaints. Baseline levels of liver function enzymes, glucose, and uric acid must be obtained before initiating therapy, and rechecked at frequent intervals during dosage increases and at regular intervals during long term therapy.
Therapy with nicotinic acid is contraindicated in persons with liver disease, gouty arthritis, peptic ulcer, significant hyperuricemia, an.d significant cardiac arrhythnuas.
New Drugs
A major advance in the treatment of hypercholesterolemia occurred when lovastatin, the first of a new family of drugs, was approved for marketing in August 1987 (Lovastatin Study Group II, 1986) . These drugs, HMG CoA Reductase Inhibitors, block the production ofHMG CoA reductase which is necessary for cholesterol production in the liver. They also increase LDL receptor-mediated removal of LDL from the plasma. The result can be as much as a 45% decrease in LDL cholesterol.
The advantages of the HMG CoA reductase inhibitors are powerful LDL lowering; a modest increase in HDL and decrease in triglycerides in some individuals; convenience in pill form and for some, once a day dosing; and a very low level of side effects and toxicity. Lovastatin is prescribed in doses from 20 to 80 mg per day and may be taken as a single evening dose or twice a day with meals.
Reported side effects, which have occurred in less than 5% of the clients, include changes in bowel function, headaches, nausea, fatigue, insomnia, and myositis (myalgia with markedly elevated CPK levels).
Approximately 1.9% of clients have developed persistent, asymptomatic increases in transaminase levels of greater than three times normal after 3 to 16 months of therapy. These elevations have gradually returned to baseline after the drug was discontinued. Nurses should reinforce the importance of having regular liver function tests during the first 18 months of therapy.
In addition to elevated transaminase levels, some concern has been raised about the possibility oflovas- Other HMG CoA reductase inhibitors currently are in various stages of development. These include symvastatin, the synthetic analogue of lovastatin; pravastatin; and fluvastatin. These drugs are being studied in clinical trials throughout the U.S. and Europe (Grundy, 1988a) . Continued refinement of this new family of drugs may result in drugs which are even more effective and less toxic than the leading agent, lovastatin.
Stoy

Other Drugs
Gemjibrozil, a fibric acid derivative, is a drug which has been used primarily for the treatment of hypertriglyceridemia. In the past, it has been used in persons with high LDL levels who were unable to tolerate standard therapy with bile acid sequestrants or nicotinic acid.
Gemfibrozil decreases VLDL, increases HDL, and modestly lowers LDL cholesterol. As the drug used in the Helsinki Heart Study (Frick, 1987) , gemfibrozil has re-4 The current national guidelines for treating hyper-• cholesterolemia offer occupational health nurses new opportunities for teaching risk reduction in the workplace. Generally, the first measurement of LDL cholesterol should be done after 1 month on therapy. A second measurement should be done after 3 months on medication. These two determinations, in conjunction with an interview to assess adherence and side effects, are essential in the assessment of the overall response to drug therapy. Additional visits may be necessary for monitoring liver function and other safety parameters.
After the appropriate LDL goal is reached, the client should be seen at 4 month intervals to assess side effects and overall response to therapy. The NCEP guidelines specify that a lipoprotein profile with an LDL cholesterol measurement two, or in some cases, three cholesterol lowering drugs. In persons with elevated LDL and normal triglycerides, the bile acid sequestrants can be safely combined with nicotinic acid or lovastatin. With such combinations, LDL lowering of up to 70% has been reported (Lees, 1986) .
For persons with elevated triglycerides and LDL levels, nicotinic acid and lovastatin are the preferred drugs. An increased risk of myositis is reported in those taking lovastatin with gernfibrozil. Since experience with lovastatin in combination with other drugs over long periods of time is limited, persons who require combination therapy should be referred to a lipid specialist for consultation. Nurses, however, should be alert to possible toxic side effects reported by clients on multiple therapies.
Ongoing studies with lovastatin will undoubtedly provide much valuable information about the efficacy and toxicities associated with various combinations of cholesterol lowering drugs.
Combination Drug Therapy Individuals with severe hypercholesterolemia will require diet therapy as well as treatment with tissue deposition of LDL cholesterol. While probucol can reduce LDL 8% to 15%, it also lowers HDL cholesterol up to 25%. Studies with probucol have, however, shown regression of xanthomas, a finding that suggests a qualitative rather than a quantitative effect of the drug (Grundy, 1988b) .
More research with probucol is needed to ascertain the safety and long term effect of the drug on CHD risk. The drug is sometimes used in persons who cannot tolerate other drugs, or in combination with drugs of first choice.
Probucol is generally well tolerated but is contraindicated in persons with ECG abnormalities, since it can cause prolongation of the QT interval.
2 The standard low fat, low cholesterol diet recommended • by the American Heart Association and the National Cholesterol Education Program restricts total fat intake to less than 30% of calories, with 10% derived from each of the three types of fats (saturated, polyunsaturated, and monounsaturated); and dietary cholesterol to less than 300 mg per day.
cently been in the spotlight and is currently being reviewed by the NCEP Adult Treatment Panel.
The participants who took gemfibrozil in the Helsinki Heart Study raised their HDL, lowered their LDL and triglycerides, and ultimately, reduced their risk of heart attack by 50%. This positive effect is the basis for the current reevaluation of gemfibrozil as a possible preferred drug for some. Gemfibrozil usually is taken as two 300 mg capsules twice a day. Side effects generally are limited to gastrointestinal complaints, although some cases of elevated liver enzymes have occurred. Gallstones have also been associated with the drug. As with all the other cholesterollowering drugs, close follow up is required.
Probucol is a cholesterol lowering drug which increases the tate of LDL catabolism and which is believed to inhibit the oxidation and
